BioIntelliSense Exit Candidate

Primary contact

🏦 Potential exit path: SPAC, M&A
Founded in 2018 by Dr. James Mault, a former cardiac surgeon at UCHealth in Colorado, BioIntelliSense is ushering in a new era of continuous health monitoring and clinical intelligence for Remote Patient Monitoring (RPM). Its medical-grade Data-as-a-Service (DaaS) platform is designed to seamlessly capture multi-parameter vital signs, physiological biometrics, and symptomatic events through an effortless patient experience. The FDA-cleared BioSticker and medical-grade BioButton devices make remote monitoring and early detection simple. Through the platform's advanced analytics, clinicians have access to high-resolution patient trending and reporting to enable medical grade care at home.
Primary contact

Funding πŸ’°

Total $82M
Last round πŸ”— $45M
Series B
July 28, 2021.
Select investors Chimera, 7wire Ventures, Pendrell Corporation, Fresenius Medical Care North America, TripleTree Holdings, UCHealth, Royal Philips

Key people πŸ§‘β€πŸ€β€πŸ§‘

Highlights ⭐

  • The Remote Patient Monitoring market is in the hyper-growth mode and is projected to reach $117.1 billion by 2025. πŸ”—
  • BioIntelliSense has managed to establish a few key partnerships
  • New CMS Medicare codes for COVID-19 and RPM align incentives and revenue capture opportunities πŸ”—
  • BioIntelliSense's founder comes from UCHealth, meaning that he knows the needs of hospitals and health systems for remote monitoring
  • It could be an attractive target for "old school" remote monitoring firms looking to modernize their offering
Last update: September 4, 2021